gorlin syndrome market

Key Highlights

• Gorlin syndrome, also known as nevoid basal cell carcinoma syndrome, is a rare inherited disorder caused by dysregulation of the hedgehog signaling pathway, most commonly due to PTCH1 mutations and less frequently SUFU or PTCH2. 
• No drugs are currently approved specifically for Gorlin syndrome, management is consequence-driven and focused on reducing basal cell carcinoma burden through hedgehog pathway inhibition.
• Systemic hedgehog pathway inhibitors such as ERIVEDGE (vismodegib) and ODOMZO (sonidegib), approved for advanced or inoperable basal cell carcinoma, are used selectively in patients with high tumor burden but are limited by tolerability and long-term safety concerns, necessitating multidisciplinary care. 
• The treatment landscape is evolving with Gorlin syndrome–specific therapies, like Itraconazole as well as SGT-610 (Patidegib gel 2%), a topical hedgehog pathway inhibitor in development designed to reduce basal cell carcinoma burden while minimizing systemic toxicity, reflecting growing recognition of unmet need and the potential for more disease-appropriate long-term management.

DelveInsight's "Gorlin Syndrome Market Insights, Epidemiology, and Market Forecast-2036" report delivers an in-depth understanding of the Gorlin Syndrome, historical and forecasted epidemiology as well as the Gorlin Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Gorlin Syndrome market report provides current treatment practices, emerging drugs, Gorlin Syndrome market share of the individual therapies, current and forecasted Gorlin Syndrome market Size from 2022 to 2036 segmented by seven major markets. The Report also covers current Gorlin Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Gorlin Syndrome market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2022-2036

Key Factors Driving the Gorlin Syndrome Market

• Increasing Treatment Uptake in Previously Undertreated Patients: A significant portion of Gorlin syndrome patients have historically gone untreated or undertreated due to a lack of disease-specific therapies. As awareness grows and more options emerge, more patients are expected to enter active treatment, expanding the market.
• Longer Duration of Therapy Driven by Chronic Disease Management Needs: Gorlin syndrome is a lifelong condition with no cure. Patients require sustained, long-term management rather than short-course treatment, meaning each patient contributes to prolonged drug utilization and revenue over time.
• Improved Patient Retention with More Tolerable Treatment Options: Existing systemic therapies like vismodegib and sonidegib are frequently discontinued due to poor tolerability. Emerging options such as SGT-610 (Patidegib gel 2%) are designed to minimize systemic toxicity, enabling patients to stay on therapy longer and improving overall retention rates.
• Orphan Nature of Gorlin Syndrome: Because Gorlin syndrome is a rare disease, therapies developed for it can qualify for orphan drug designation, which brings regulatory incentives such as extended market exclusivity, reduced filing fees, and faster review timelines, all of which support favorable market conditions.
• Limited Therapeutic Competition: There are currently no pharmacologic therapies approved specifically for Gorlin syndrome. Any therapy that achieves Gorlin syndrome-specific approval would enter a largely non-competitive market, offering a significant first-mover advantage.
• Potential Regulatory Incentives: Pipeline therapies such as SGT-610 already carry Orphan Drug Designation (ODD) and Breakthrough Therapy Designation (BTD), which accelerate development timelines and strengthen the commercial case for investment, further driving market growth.
  

Gorlin Syndrome Disease Understanding and Treatment Algorithm

Gorlin syndrome, also known as nevoid basal cell carcinoma syndrome, is a rare inherited disorder caused by dysregulation of the hedgehog signaling pathway, most commonly due to PTCH1 mutations and less frequently SUFU or PTCH2 mutations. This molecular abnormality drives abnormal cell proliferation and developmental anomalies, resulting in a lifelong predisposition to multiple basal cell carcinomas, odontogenic jaw keratocysts, skeletal abnormalities, and select malignancies. The disease represents a lifelong tumor-predisposition condition in which developmental pathway dysregulation drives continuous neoplastic risk rather than episodic disease activity.

Diagnosis of Gorlin syndrome is primarily clinical with genetic confirmation, based on established diagnostic criteria that include early-onset multiple basal cell carcinomas, jaw keratocysts, palmar or plantar pits, calcification of the falx cerebri, and characteristic skeletal or craniofacial features. Genetic testing supports diagnosis, long-term surveillance planning, and family counseling, while imaging modalities such as panoramic radiography, CT, or magnetic resonance imaging (MRI) are used adjunctively to detect jaw, skeletal, or intracranial abnormalities rather than to monitor disease activity.

Management of Gorlin syndrome is consequence-driven and multidisciplinary, as no drugs are currently approved specifically for the condition. Non-pharmacologic interventions focus on lifelong surveillance, UV avoidance, and early lesion management, forming the cornerstone of care. Systemic hedgehog pathway inhibitors such as vismodegib (ERIVEDGE) and sonidegib (ODOMZO), approved for advanced or inoperable basal cell carcinoma, are used selectively in patients with high tumor burden but are limited by tolerability and long-term safety concerns. The treatment landscape is evolving with emerging therapies such as SGT-610 (patidegib gel 2%), a topical hedgehog pathway inhibitor designed to reduce basal cell carcinoma burden while minimizing systemic toxicity, and itraconazole, which is being explored for its effects on the hedgehog signaling pathway.

Gorlin Syndrome Diagnosis

Diagnosis of Gorlin syndrome is primarily clinical with genetic confirmation, based on established diagnostic criteria that include early-onset multiple basal cell carcinomas, jaw keratocysts, palmar or plantar pits, calcification of the falx cerebri, and characteristic skeletal or craniofacial features. Genetic testing supports diagnosis, long-term surveillance planning, and family counseling, while imaging modalities such as panoramic radiography, CT, or magnetic resonance imaging (MRI) are used adjunctively to detect jaw, skeletal, or intracranial abnormalities rather than to monitor disease activity.

Gorlin Syndrome Treatment

Management of Gorlin syndrome is consequence-driven and multidisciplinary, as no drugs are currently approved specifically for the condition. Non-pharmacologic interventions focus on lifelong surveillance, UV avoidance, and early lesion management, forming the cornerstone of care. Systemic hedgehog pathway inhibitors such as vismodegib (ERIVEDGE) and sonidegib (ODOMZO), approved for advanced or inoperable basal cell carcinoma, are used selectively in patients with high tumor burden but are limited by tolerability and long-term safety concerns. The treatment landscape is evolving with emerging therapies such as SGT-610 (patidegib gel 2%), a topical hedgehog pathway inhibitor designed to reduce basal cell carcinoma burden while minimizing systemic toxicity, and itraconazole, which is being explored for its effects on the hedgehog signaling pathway.

Gorlin Syndrome Epidemiology 

The Gorlin Syndrome epidemiology section provides insights about the historical and current Gorlin Syndrome patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Gorlin Syndrome market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Gorlin Syndrome epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2022 to 2036.

• In the United States, the estimated prevalence of Gorlin syndrome is approximately 1 in 31,000 individuals, accounting for fewer than 1% of the more than one million basal cell carcinoma cases diagnosed annually. The condition affects males and females equally and clinical manifestations typically begin in childhood or early adulthood.
• In the United Kingdom, reported prevalence estimates range from 1 in 55,600 to 1 in 30,827, with similar rates in males and females. Genetic testing identified PTCH mutations in 61% of tested individuals, supporting the role of molecular confirmation in diagnosis and family screening.
• Ovarian fibromas represent a clinically relevant but under-recognized manifestation of Gorlin syndrome, affecting at least 12.5% of Japanese and 25% of UK female patients, often presenting bilaterally and with calcification.

Gorlin Syndrome Drug Chapters

The drug chapter segment of the Gorlin Syndrome report encloses the detailed analysis of Gorlin Syndrome marketed drugs and late-stage (Phase-III and Phase-II) Gorlin Syndrome pipeline drugs. It also helps to understand the Gorlin Syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Gorlin Syndrome Marketed Drugs

ERIVEDGE (vismodegib): A systemic hedgehog pathway inhibitor approved for advanced or inoperable basal cell carcinoma, used off-label in Gorlin syndrome patients with high tumor burden across the US, Europe, and Japan.

ODOMZO (sonidegib): A systemic hedgehog pathway inhibitor also approved for advanced basal cell carcinoma and similarly used in Gorlin syndrome patients. Long-term use of both agents is frequently limited by class-related adverse effects such as muscle cramps, dysgeusia, alopecia, and weight loss.

Gorlin Syndrome Emerging Drugs

SGT-610 (Patidegib gel): Sol-Gel technologies

SGT-610, a topical hedgehog signaling pathway inhibitor, has the potential to be the first ever preventive treatment for Gorlin syndrome, if approved. Patidegib gel 2% is designed to replace PTCH activity by inhibiting Smo and blocking the hedgehog signaling pathway, so the cells stop dividing. Inhibiting the hedgehog signaling pathway prevents new BCCs from growing. 

Itraconazole: Inhibitor Therapeutics

Itraconazole is a broad-spectrum triazole antifungal agent used for the treatment of systemic and superficial fungal infections. It is widely available as a generic drug, with multiple manufacturers producing oral and intravenous formulations following the expiration of patent exclusivity for the originator product. While its primary indication remains antifungal therapy, itraconazole has also been explored in oncology and rare disease settings due to its effects on pathways such as Hedgehog signaling, although such uses remain investigational.

Latest Developments 

• In March 2026, Sol-Gel Technologies reported the pricing of an underwritten public offering of 459,112 ordinary shares at USD 72.00 per share, generating gross proceeds of approximately USD 33.1 million. The company expects the offering to close in March 2026 and plans to use the proceeds to support the development and pre-commercialization of SGT-610, along with general corporate purposes. 
• In March 2026, Inhibitor Therapeutics reported clinical, formulation, and intellectual property updates for its itraconazole program in Gorlin syndrome (BCCNS). The company highlighted ongoing pharmacokinetic studies of a proprietary amorphous formulation designed to improve solubility and absorption, with topline PK results expected in mid-2026 to support a potential NDA submission under the FDA’s 505(b)(2) pathway. The company also plans to file a global patent application covering the novel formulation.
• In November 2025, Sol-Gel Technologies reported that its ongoing Phase III trial of SGT-610 (Patidegib gel, 2%) for Gorlin syndrome continues to progress, with top-line results expected in Q4 2026. The company highlighted expanding interest in compassionate use for patients with severe, high-frequency basal cell carcinoma (BCC) harboring PTCH1 mutations, and is evaluating a feasibility study to support a Phase III trial in this population in 2027. 

Gorlin Syndrome Market Outlook

The Gorlin Syndrome market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Gorlin Syndrome market trends by analyzing the impact of current Gorlin Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Gorlin Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Gorlin Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Gorlin Syndrome market in 7MM is expected to witness a major change in the study period 2022-2036.

Key Findings

This section includes a glimpse of the Gorlin Syndrome market in 7MM.

The United States Market Outlook

This section provides the total Gorlin Syndrome market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Gorlin Syndrome market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Gorlin Syndrome market size and market size by therapies in Japan is also mentioned.

Gorlin Syndrome Drugs Uptake

This section focuses on the rate of uptake of the potential Gorlin Syndrome drugs recently launched in the Gorlin Syndrome market or expected to get launched in the market during the study period 2022-2036. The analysis covers Gorlin Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Gorlin Syndrome Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Gorlin Syndrome market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Gorlin Syndrome Pipeline Development Activities

The Gorlin Syndrome report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Gorlin Syndrome key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Gorlin Syndrome report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Gorlin Syndrome emerging therapies.

Reimbursement Scenario in Gorlin Syndrome

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Gorlin Syndrome market trends, we take KOLs and SMEs ' opinion working in the Gorlin Syndrome domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Gorlin Syndrome market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Gorlin Syndrome Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Gorlin Syndrome, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Gorlin Syndrome epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Gorlin Syndrome is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Gorlin Syndrome market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Gorlin Syndrome market

Report Highlights

• In the coming years, the Gorlin Syndrome market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Gorlin Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Gorlin Syndrome. The launch of emerging therapies will significantly impact the Gorlin Syndrome market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Gorlin Syndrome
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Gorlin Syndrome Report Insights

• Gorlin Syndrome Patient Population
• Therapeutic Approaches
• Gorlin Syndrome Pipeline Analysis
• Gorlin Syndrome Market Size and Trends
• Gorlin Syndrome Market Opportunities
• Impact of upcoming Gorlin Syndrome Therapies

Gorlin Syndrome Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Gorlin Syndrome Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Gorlin Syndrome Report Assessment

• Current Treatment Practices
• Unmet Needs
• Gorlin Syndrome Pipeline Product Profiles
• Gorlin Syndrome Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What was the Gorlin Syndrome drug class share (%) distribution in 2022 and how it would look like in 2036?
• What would be the Gorlin Syndrome total market size as well as market size by therapies across the 7MM during the forecast period (2022-2036)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Gorlin Syndrome market size during the forecast period (2022-2036)?
• At what CAGR, the Gorlin Syndrome market is expected to grow by 7MM during the forecast period (2022-2036)?
• What would be the Gorlin Syndrome market outlook across the 7MM during the forecast period (2022-2036)?
• What would be the Gorlin Syndrome market growth till 2036, and what will be the resultant market Size in the year 2036?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Gorlin Syndrome?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Gorlin Syndrome patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Gorlin Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Gorlin Syndrome?
• Out of all 7MM countries, which country would have the highest prevalent population of Gorlin Syndrome during the forecast period (2022-2036)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2022-2036)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Gorlin Syndrome treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Gorlin Syndrome in the USA, Europe, and Japan?
• What are the Gorlin Syndrome marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Gorlin Syndrome?
• How many therapies are in-development by each company for Gorlin Syndrome treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Gorlin Syndrome treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Gorlin Syndrome therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Gorlin Syndrome and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Gorlin Syndrome?
• What are the global historical and forecasted market of Gorlin Syndrome?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Gorlin Syndrome market
• To understand the future market competition in the Gorlin Syndrome market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Gorlin Syndrome in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Gorlin Syndrome market
• To understand the future market competition in the Gorlin Syndrome market